Is Retatrutide Legal or FDA-Approved? Compounding, Lawsuits & Status, November 2026

Key takeaways

Retatrutide is not approved anywhere. Lilly says no medicine containing it “has yet been approved for human use by any regulatory agency in the world.”
FDA says retatrutide “cannot be used in compounding under federal law”. The 30 October 2026 HHS peptide policy covers six other peptides and does not include it.
FDA has warned telehealth companies, ingredient distributors, outsourcing facilities and “research use” sellers over retatrutide. Lilly announced six lawsuits on 12 August 2026, and court records show five more filed on 8 October.
FDA classified retatrutide as a drug, not a biologic, again on 2 October 2026. Lilly is appealing. The approval route is still unsettled, and so is the date.

Is retatrutide legal in the US?

No product containing retatrutide can be lawfully sold for human use in the US today. Retatrutide is an investigational drug in Lilly’s Phase 3 programme, and Lilly says it “cannot be sold to consumers” (Lilly, 12 Aug 2026). FDA’s GLP-1 page, current as of 1 October 2026, says retatrutide “cannot be used in compounding under federal law” and “[has] not been found safe and effective for any condition” (FDA).

So none of the three legal channels described in our research-use-only vs compounded vs approved guide is open to it. There is no approved product, compounding is ruled out, and FDA has said products “falsely labeled ‘for research purposes’” have been sold to consumers with dosing instructions (FDA).

What is retatrutide?

Retatrutide is an investigational molecule developed by Eli Lilly that acts on three hormone receptors: GIP, GLP-1 and glucagon (AJMC). Lilly describes it as being in “Phase 3 clinical trials for obesity, type 2 diabetes and other related indications” (Lilly).

That makes it different from semaglutide and tirzepatide. Those two are active ingredients of FDA-approved drugs, so the compounding questions around them are about shortages, salt forms and copies. With retatrutide, there is no approved product at all. This page covers regulatory status only. It does not discuss trial results, dosing or effects.

Can a pharmacy compound retatrutide?

No. FDA states that “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs” (FDA).

The HHS enforcement discretion policy published on 30 October 2026 does not change this. Its Appendix A lists exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 (HHS Appendix A). Retatrutide is not on it. What the policy does cover is explained in HHS’s peptide compounding policy explained. For the difference between pharmacy and outsourcing-facility compounding, see 503A vs 503B.

Channel	Status for retatrutide	Source
FDA-approved drug	None. No regulator anywhere has approved it	Lilly
503A / 503B compounding	“Cannot be used in compounding under federal law”	FDA
HHS six-peptide policy	Not listed in Appendix A	HHS
“Research use only” listings	FDA has warned sellers whose sites showed human use	FDA; WL 733652
Clinical trials	The only channel in which people receive it under FDA oversight	Lilly

What has FDA done about retatrutide sales?

FDA lists three groups it has warned over retatrutide (FDA):

“Telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers.”
“Active pharmaceutical ingredient distributors for selling retatrutide and other GLP-1 drugs to compounders.”
“Outsourcing facilities for repackaging retatrutide.”

Separately, FDA says it has warned companies selling semaglutide, tirzepatide, retatrutide, survodutide or mazdutide “falsely labeled ‘for research purposes’ or ‘not for human consumption’” (FDA). One example is warning letter 733652 of 24 August 2026. It named a product listed as “GLP-3 RT (Retatrutide) Research Peptide” as an unapproved new drug, despite the site’s research-use labels (FDA warning letter 733652).

Coded product names

Retatrutide is often listed under abbreviations such as “RT”, “Reta” or “GLP-3”. The Victorian health alert lists “Reta”, “R-10” and “R-20” among the product labels involved (Victoria Department of Health). A different name does not change the substance. FDA’s 2026 warning letters have named products listed under abbreviated or coded names. Our COA verification guide explains how to check what identity a lab report actually confirms.

Who is Lilly suing over retatrutide?

On 12 August 2026 Lilly announced six lawsuits against US entities, describing the targets as “compounding pharmacies, medical spas, and online sellers that falsely claim their drugs are for ‘research-use only’ when they are actually intended for human use” (Lilly). The same release says Lilly has:

referred “more than 200 individuals and entities” to FDA, the Department of Justice, state attorneys general, law enforcement and licensing boards;
reported “more than 14,000 websites, advertisements, social media posts and product listings” in over 100 countries;
called on “credit card companies, payment processors, shipping and logistics companies” and online platforms to “cut off the infrastructure enabling this illegal trade”.

A docket review published by Jabbit on 27 October counts 11 federal suits: the six from August plus five filed on 8 October. By that count, Lilly ended three by voluntary dismissal with prejudice. The notices state no terms. One defendant has moved to dismiss, arguing that Lilly lacks standing because it does not sell retatrutide itself, and a case conference is set for 30 November (Jabbit docket review, secondary). No court has ruled on the merits. The complaints are allegations, and we do not name defendants here. We found no case brought against a buyer.

For sellers, Lilly’s call to payment companies matters as much as the lawsuits. It ties into the processor risk described in how payment processors underwrite peptide companies.

Is retatrutide a drug or a biologic, and why does it matter?

The approval route depends on how FDA classifies the molecule. Under 21 CFR 600.3(h)(6), a “protein”, and therefore a biologic, is an alpha amino acid polymer “greater than 40 amino acids in size”. According to Peptide Policy Watch’s review of the court record, FDA counts 39 alpha amino acids in retatrutide’s backbone. Lilly counts 41 by including two units in a side chain, which FDA says are not alpha amino acids (Peptide Policy Watch, secondary).

Date	Step
Mar 2024	FDA classifies retatrutide as a drug. Lilly sues in the Southern District of Indiana in September 2024
30 Sep 2025	The court upholds FDA on the “protein” question and sends the “analogous product” question back to FDA
24 Sep 2026	Lilly’s appeal is argued in the Seventh Circuit
2 Oct 2026	On remand, FDA again finds retatrutide is a drug, not a biologic
8 Oct 2026	Jurisdiction briefs filed. Lilly says it plans to file its application by the end of Q1 2027

Timeline as reported by Peptide Policy Watch from the court filings (source). It found no appellate ruling as of 3 November 2026. The classification decides which statute an application is filed under, and with it how long exclusivity lasts after approval. It does not decide whether retatrutide is approved. Either way, FDA’s drug centre would review it.

What safety reports have regulators published?

These are reports, not established causal findings, and each source says so:

Victoria, Australia (19 June 2026): six cases of acute liver injury since January 2026 in people who used unapproved products labelled retatrutide. The Chief Health Officer says the effects are “possibly associated with a contaminant” and that “all such products are at risk” (health alert).
US adverse event reports (CBS News, 13 October 2026): two deaths reported to FDA’s adverse event system after use of products claimed to be retatrutide. CBS says the details are unverified and it is unclear whether the product was to blame (CBS News).
US poison centres: America’s Poison Centers logged 249 retatrutide exposures in Q1 2026, 460 in Q2 and 862 in Q3, as reported by CBS (CBS News). An exposure is a call to a poison centre, not proof of harm.

The common thread is identity. Nobody outside the trial programme can confirm what an unapproved vial contains, a point our testing-standard explainer covers in detail.

Can retatrutide be advertised or processed?

Ad platforms and payment providers set their own rules, separate from FDA. Google’s Unapproved Substances policy is the usual barrier on the advertising side. On the payments side, Stripe’s terms prohibit “incorrectly labeled research chemicals” and Adyen restricts “peptides, research chemicals”, as covered in our payment processing guide. Our Unapproved Substances policy guide covers the advertising side. Lilly has publicly asked platforms and processors to act against retatrutide listings (Lilly), so expect more enforcement rather than less.

What about outside the US?

Lilly’s statement that no regulator anywhere has approved retatrutide covers every market (Lilly). Australia’s Victorian health department calls it “an experimental drug not approved for sale” there (Victoria). Country-by-country import and medicines rules are beyond this page. Our regulatory tracker follows the US federal record.

Sources

Checked 11 November 2026. This page describes legal and regulatory status only. It is not medical or legal advice and makes no claims about retatrutide’s safety or effects.

Reader Question

“Now that HHS relaxed the rules on peptides, is retatrutide allowed?”

Short Answer

No. The HHS policy covers six named peptides, and retatrutide is not one of them. FDA says it cannot be used in compounding, and no regulator has approved it.

Practical Recommendation

Treat any product sold as retatrutide, “RT”, “Reta” or “GLP-3” as an unapproved drug, whatever the label says.
Do not read the HHS six-peptide policy as covering GLP-1-class research peptides. Retatrutide is not in Appendix A.
Watch the Seventh Circuit appeal and Lilly’s planned Q1 2027 filing for the next change in status.

What we learned

Retatrutide is the clearest case in the peptide market of a substance with no lawful channel at all. Every route other than a clinical trial is closed, and the pressure on sellers now comes from FDA, a well-funded drug developer and the payment and platform companies Lilly has asked to act. A listing’s name or label does not change that.

Frequently asked

Is retatrutide FDA-approved?

No. Lilly says no medicine containing retatrutide has been approved for human use by any regulator in the world. It is in Phase 3 trials.

Can I get compounded retatrutide legally?

No. FDA says retatrutide cannot be used in compounding under federal law, and the October 2026 HHS peptide policy does not include it.

Does a “research use only” label make retatrutide legal to sell?

Not on its own. FDA has warned sellers whose labels said research use only when their websites showed the products were intended for people.

When could retatrutide be approved?

No date is known. Lilly has said it plans to submit an application by the end of Q1 2027, and the drug-versus-biologic dispute affects which route it uses. FDA review takes time after that.

Is Lilly suing people who bought retatrutide?

The suits we found target sellers, clinics and a compounding pharmacy. We found no case brought against a buyer.

Explore the directory

Compare companies, suppliers and testing laboratories in the Peptide Ad Lab index. Every profile separates what we verified from what a company claims.

Browse companies Supplier comparisons Testing facilities

Is Retatrutide Legal? FDA Status, Compounding, and Lilly’s Lawsuits (November 2026)